Amarin (AMRN)

Amarin is a rapidly growing, innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From its scientific research foundation to its focus on clinical trials, and now its commercial expansion, it is evolving and growing. In 2009, Amarin had fewer than twenty employees. Today, with offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, and Zug in Switzerland, Amarin has approximately 1,000 employees and commercial partners and suppliers around the world. It is committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management.

Company profile

Ticker

AMRN

Exchange

NASDAQ

Website

www.amarincorp.com

CEO

John Thero

Incorporated

United Kingdom

Location

Ireland

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Abbvie ...

Former names

AMARIN PHARMACEUTICALS PLC, ETHICAL HOLDINGS PLC

SEC CIK

0000897448

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Amarin Pharmaceuticals Ireland Limited • Amarin Pharma, Inc. • Ester Neurosciences Limited • Amarin Switzerland GmbH • Amarin Germany GmbH • Amarin France SAS • Amarin UK Limited • Amarin Belgium, branch of Amarin Switzerland GmbH • Amarin Denmark, filial af Amarin Switzerland GmbH • Amarin Switzerland GmbH ...

AMRN stock data

1M 1Y 5Y

News

From Benzinga Pro

Amarin Corp Earnings Perspective: Return On Capital Employed

8 Aug 22

Amarin Still Suspends FY22 Guidance On Generic Challenges

3 Aug 22

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial

3 Aug 22

Here's a roundup of top developments in the biotech space over the last 24 hours:

This Healthcare Stock Is Trading Higher By 148%: Here Are 40 Stocks Moving Premarket

3 Aug 22

Amarin Corp: Q2 Earnings Insights

3 Aug 22

Press releases

From Benzinga Pro

Amarin Reports Second Quarter 2022 Financial Results and Provides Business Update

3 Aug 22

Company Received Final Positive Reimbursement Decision for VAZKEPA® by UK's NICE in England & Wales Market Access Negotiations and Launch Preparations for VAZKEPA Underway Across Multiple European Markets

HLS announces that Vascepa® is now reimbursed by the Saskatchewan Drug Plan

2 Aug 22

Reimbursement coverage for Vascepa in Canada is now approximately 70% for publicly covered lives and private coverage is now in excess of 95% for those that are in-labelPublic reimbursement for Vascepa is now available

HLS Announces that Vascepa® is now reimbursed by Ontario's Provincial Drug Plan

25 Jul 22

Reimbursement for Vascepa in Canada is now at more than 65% for publicly covered lives and private coverage is in excess of 95% for those who are in-labelPublic reimbursement for Vascepa is now available in Ontario,

Amarin to Report Second Quarter 2022 Financial Results and Host Conference Call on August 3, 2022

20 Jul 22

REDUCE-IT Exploratory Post Hoc Biomarker Sub-Analysis Shows Relatively Small Changes in Inflammatory Markers Between Icosapent Ethyl and Placebo

30 Jun 22

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

3 Aug 22

12 Aug 22

31 Dec 22

Financial summary

Financial statements Chart AMRN financial data

Quarter (USD)	Jun 22	Mar 22	Dec 21	Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	228M	228M	228M	228M	228M	228M
Cash burn (monthly)	(no burn)	8.25M	21.6M	7.49M	21.53M	16.35M
Cash used (since last report)	n/a	11.82M	30.93M	10.72M	30.83M	23.42M
Cash remaining	n/a	216.18M	197.07M	217.28M	197.17M	204.58M
Runway (months of cash)	n/a	26.2	9.1	29.0	9.2	12.5

Beta Read what these cash burn values mean

Financial data from Amarin earnings reports.

Recent insider trades

AMRN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
1 Aug 22	Michael Wayne Kalb	Ordinary Shares	Payment of exercise	Dispose F	No	No	1.33	29,682	39.48K	337,314
29 Jul 22	Michael Wayne Kalb	Ordinary Shares	Payment of exercise	Dispose F	No	No	1.33	17,220	22.9K	284,662
29 Jul 22	Michael Wayne Kalb	Ordinary Shares	Option exercise	Acquire M	No	No	0	47,767	0	301,882
29 Jul 22	Michael Wayne Kalb	RSU Ordinary Shares	Option exercise	Dispose M	No	No	0	47,767	0	95,533
29 Jul 22	Aaron Berg	Ordinary Shares	Payment of exercise	Dispose F	No	No	1.33	8,181	10.88K	411,155
29 Jul 22	Aaron Berg	Ordinary Shares	Option exercise	Acquire M	No	No	0	23,884	0	419,336
29 Jul 22	Aaron Berg	RSU Ordinary Shares	Option exercise	Dispose M	No	No	0	23,884	0	47,766
29 Jul 22	Steven B Ketchum	Ordinary Shares	Payment of exercise	Dispose F	No	No	1.33	8,181	10.88K	512,615
29 Jul 22	Steven B Ketchum	Ordinary Shares	Option exercise	Acquire M	No	No	0	23,884	0	520,796
29 Jul 22	Steven B Ketchum	RSU Ordinary Shares	Option exercise	Dispose M	No	No	0	23,884	0	47,766

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

AMRN institutional ownership history Ownership history

32.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	222	235	-5.5%
Opened positions	31	50	-38.0%
Closed positions	44	45	-2.2%
Increased positions	53	51	+3.9%
Reduced positions	51	60	-15.0%

13F shares	Current	Prev Q	Change
Total value	424.01M	456.01M	-7.0%
Total shares	127.76M	132.79M	-3.8%
Total puts	2.71M	4.49M	-39.6%
Total calls	1.22M	1.96M	-37.8%
Total put/call ratio	2.2	2.3	-2.8%

Largest owners	Shares	Value	Change
Sarissa Capital Management	24M	$78.96M	+24.7%
Baker Bros. Advisors	21.17M	$69.65M	0.0%
Eversept Partners	8.98M	$29.55M	-15.1%
SCP Investment	6.75M	$22.21M	0.0%
Avoro Capital Advisors	6M	$19.74M	0.0%
Stonepine Capital Management	4.91M	$16.16M	NEW
Millennium Management	4.89M	$16.07M	+45.0%
Clearbridge Advisors	4.79M	$15.76M	+0.9%
MS Morgan Stanley	4.64M	$15.26M	-4.0%
Rock Springs Capital Management	4.42M	$14.54M	0.0%

Largest transactions	Shares	Bought/sold	Change
BVF	0	-16.46M	EXIT
Stonepine Capital Management	4.91M	+4.91M	NEW
Sarissa Capital Management	24M	+4.75M	+24.7%
13D Management	2.02M	+2.02M	NEW
Eversept Partners	8.98M	-1.59M	-15.1%
Millennium Management	4.89M	+1.52M	+45.0%
Citadel Advisors	2.41M	+1.21M	+101.4%
Two Sigma Investments	2.06M	+1.06M	+106.5%
Anson Funds Management	0	-750K	EXIT
Susquehanna International	912.18K	-743.73K	-44.9%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Ionis Pharmaceuticals • Astrazeneca • Portage Biotech • Novartis • Intercept Pharmaceuticals • Acasti Pharma • Cardax • Abbvie • Matinas Biopharma • NeuroBo Pharmaceuticals

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: amid, atherogenic, Brunswick, CCS, commodity, compromise, concordant, economy, elaborated, Excellence, fasting, FDC, geopolitical, German, impossible, intolerance, Intolerant, invasion, macroeconomic, magnify, military, NHS, NICE, Northwest, organizational, peripheral, pharmacologic, pro, prudent, rata, refining, relaxed, reorganization, Russia, stepwise, Ukraine, unsellable, unvested, voluntarily, workplace

Removed: advantage, ahead, anticipation, atherosclerotic, CDC, comparison, conference, consequentially, distracting, emphasize, enrolment, expertise, forward, fragile, fulfillment, gaining, heard, honor, improving, justified, litigate, maximize, medication, mitigated, objective, opted, ordering, outlined, prepare, proactive, reportedly, resumption, rightsized, scalable, summer, surprisingly, thousand, unfilled, unwilling, wait

From filing 10-Q 2022 Q2

Financial reports

View all